Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity
Open Access
- 5 January 2015
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 7 (6) , 2805-2811
Abstract
Chemosensitizers can improve the therapeutic index of chemotherapy and overcome treatment resistance. Successful translation of chemosensitizers depends on the development of strategies that can preferentially deliver chemosensitizers to tumors while avoiding normal tissue. We hypothesized that nanoparticle (NP) formulation of chemosensitizers can improve their delivery to tumors which can in turn improve their therapeutic index. To demonstrate the proof of principle of this approach, we engineered NP formulations of two chemosensitizers, the PI3-kindase inhibitor wortmanin (Wtmn) and the PARP inhibitor olaparib. NP Wtmn and NP olaparib were evaluated as chemosensitizers using lung cancer cells and breast cancer cells respectively. We found Wtmn to be an efficient chemosensitizer in all tested lung-cancer cell lines reducing tumor cell growth between 20 and 60% compared to drug alone. NP formulation did not decrease its efficacy in vitro. Olaparib showed less consistent chemosensitization as a free drug or in NP formulation. NP Wtmn was further evaluated as a chemosensitizer using mouse models of lung cancer. We found that NP Wtmn is an effective chemosensitizer and more effective than free Wtmn showing a 32% reduction in tumor growth compared to free Wtmn when given with etoposide. Importantly, NP Wtmn was able to sensitize the multi-drug resistant H69AR cells to etoposide. Additionally, the combination of NP Wtmn and etoposide chemotherapy did not significantly increase toxicity. The present study demonstrates the proof of principle of using NP formulation of chemosensitizing drugs to improve the therapeutic index of chemotherapy.Keywords
Funding Information
- National Institutes of Health (R01CA178748-01)
This publication has 21 references indexed in Scilit:
- Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitorsBioorganic & Medicinal Chemistry, 2013
- PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving TargetsFrontiers in Oncology, 2013
- Revival of the abandoned therapeutic wortmannin by nanoparticle drug deliveryProceedings of the National Academy of Sciences, 2012
- Folate-Targeted Polymeric Nanoparticle Formulation of Docetaxel Is an Effective Molecularly Targeted Radiosensitizer with Efficacy Dependent on the Timing of RadiotherapyACS Nano, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the ClinicCancer Research, 2010
- Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.2000
- Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJournal of Controlled Release, 2000
- Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.1997